Andrea Walsh serves as Independent Director of the Company. Since 2017 she has served as President and CEO of HealthPartners, a Minnesota-based non-profit integrated health system caring for 1.2 million patients and providing health insurance and well-being support to 1.8 million health plan members. Previously, she served as its Executive Vice President and Chief Marketing Officer from 2002 to May 2017 and as its Senior Vice President and Corporate Counsel from 1994 to 1999. Ms. Walsh holds Business Administration and English degrees from the University of Kansas and a Juris Doctorate from the University of Minnesota Law School. She currently serves on the boards of directors of Constellation (a medical professional liability mutual insurance company), YMCA of the North, and the Amherst H. Wilder Foundation. Our Board believes that Ms. Walsh’s experience as the top executive at one of the nation’s largest health care organizations will provide new and enhanced insight into a key aspect of our company’s business in addition to valuable leadership experience.
Andrea Walsh is 57, she's been the Independent Director of Electromed since 2020. There are 7 older and 3 younger executives at Electromed. The oldest executive at Electromed Inc. is George Winn, 83, who is the Independent Director.
Andrea's mailing address filed with the SEC is 500 SIXTH AVENUE NW, , NEW PRAGUE, MN, 56071.
Over the last 14 years, insiders at Electromed have traded over $2,585,226 worth of Electromed stock and bought 684,801 units worth $2,582,707 . The most active insiders traders include Oak Partners, Llc Red, Stephen H. Craney a Kathleen Skarvan. On average, Electromed executives and independent directors trade stock every 84 days with the average trade being worth of $358,798. The most recent stock trade was executed by James L. Cunniff on 1 March 2024, trading 9,000 units of ELMD stock currently worth $137,250.
electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.
Electromed executives and other stock owners filed with the SEC include: